Why the study?
Does warfarin reduce ischemic stroke in patients with atrial fibrillation and end-stage renal disease?
Does warfarin reduce ischemic stroke in patients with atrial fibrillation and end-stage renal disease?
The optimal strategy for stroke prevention in AF patients with ESRD undergoing dialysis remains unknown due to conflicting observational data and a lack of randomized controlled trials.
CKD heightens stroke and bleeding risks in AF; leaves open optimal prevention strategies for ESRD on dialysis.
Chronic kidney disease (CKD) has been identified as an important risk factor for new-onset atrial fibrillation (AF) and would significantly increase the risk of AF-related strokes. Stroke prevention in AF patients with CKD is a big challenge, especially for patients with end-stage renal disease (ESRD) undergoing long-term dialysis. In addition to an increase risk of stroke, renal dysfunction was also associated with a higher risk of hemorrhage due to dysregulation of coagulation and uremia-mediated platelet dysfunction. Therefore, the net clinical benefit balancing stroke risk reduction and increased risk of bleeding should be weighed carefully before initiating oral anti-coagulants for ESRD patients. Several studies investigating whether warfarin should be used for stroke prevention in AF patients with ESRD have been published and showed inconsistent results. Since none of these studies was a prospective and randomized trial, the best strategy for stroke prevention in AF patients with ESRD undergoing dialysis remained unknown and more data are necessary to answer this issue.
No takes yet. Share an insight, caveat, or question.
Chao et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: